Jeffrey A. Bluestone
Chairman of Scientific Advisory BoardDr. Jeffrey A. Bluestone, PhD., M.D., AW, UCSF, also known as Jeff, serves as Managing Director at Vie Ventures since February 2026. He is Member of Scientific Advisory Board of Cimeio Therapeutics AG. Dr. Bluestone served as Member of Medical Advisory Board at Targazyme, Inc. He has been an Independent Director at Gilead Sciences, Inc. since December 7, 2020. Dr. Bluestone is a Scientific Advisor of Vir Biotechnology Inc. He had been an Independent Director at Provention Bio, Inc. since 2013 until June 2022. He Founded Sonoma Biotherapeutics, Inc. and served as its Advisor since November 17, 2025 until March 2026 and was its Chief Executive Officer and President since 2019 until November 17, 2025. He also served as a Board Member of Sonoma Biotherapeutics, Inc. until March 2026. Dr. Bluestone is Founder of Celsius Therapeutics, Inc. Dr. Bluestone served as President and Chief Executive Officer of Parker Institute for Cancer Immunotherapy from June 2015 to December 2019. He serves as Member of Scientific Advisory Board at Arcus Biosciences, Inc. He had been the A.W. and Mary Margaret Clausen Distinguished Professor of Medicine, Pathology, Microbiology & Immunology and the Director of the Hormone Research Institute in the Diabetes Center at the University of California, San Francisco (UCSF) since 2000 until December 2019. Dr. Bluestone served as Executive Vice Chancellor and Provost at the University of California San Francisco from 2010 to 2015. Dr. Bluestone serves as Member of Scientific Advisory Board at Solid Biosciences Inc. He served as a Consultant at EpiVax, Inc. He is an expert in diabetes and immunology. He was Immune Modulation Program Advisor and Member of Type 1 Diabetes Scientific Advisory Board at Caladrius Biosciences, Inc. until 2018. He serves as Scientific Advisor of Juno Therapeutics Inc. Dr. Bluestone served as Clinical Advisor of ViaCyte, Inc. (formerly, Novocell, Inc.) and served as its Member of Scientific Advisory Board until November 24, 2016. He serves as Member of Scientific Advisory Board of Kadmon Holdings, Inc. (also known as, Kadmon Corporation, LLC) and Trubion Pharmaceuticals Inc. He serves as Director of the UCSF Diabetes Center and the Juvenile Diabetes Research Foundation Collaborative Center for Cellular Therapy. He serves as Member of Advisory Board of CareDx, Inc. Dr. Bluestone was the Founding Director of The Immune Tolerance Network, an international program to advance clinical research in immune tolerance. He served on the board of Rheos Medicines since 2017. Dr. Bluestone serves as a Member of the Howard Hughes Medical Institute Scientific Advisory Board and the National Council on Aging. He served as Member of Scientific Advisory Board of MannKind Corporation. He served as Member of Scientific Advisory Board at FLX Bio., Inc. He served as Member of the Scientific Advisory Board at Bayhill Therapeutics, Inc. He served as a Member of Advisory Board of Emergent Product Development Seattle LLC. He served as a Member of Scientific Advisory Board of Sirna Therapeutics, Inc. since March 2006. He served as Member of Scientific Advisory Board at Xcyte Therapies Inc. and EpiVax, Inc. He served as Member of Scientific Advisory Board of Converge Medical, Inc. He served on several high-profile editorial boards and serves on several institutional and NIH advisory boards. Through his scientific career, he has authored more than 300 peer-reviewed publications that include prominent papers in Nature, Nature Immunology and the Journal of Immunology and Diabetes. He has received numerous accolades for his work, including his 2006 election to the American Academy of Arts and Sciences, the Mary Tyler Moore & Robert Levine Excellence in Clinical Research Award from the Juvenile Diabetes Research Foundation and the Distinguished Alumni Award from the Cornell Graduate School of Medical Science. Dr. Bluestone has made toward elucidating the biological basis for immunologic tolerance. He has authored over 275 publications. He has received numerous honors and awards, including the American Cancer Society Faculty Scholar Award, the Cornell Medical School Distinguished Alumni Award, a Guggenheim Senior Fellowship, a Fogarty Senior Research Fellowship and a Daniel K. Ludwig Professorship. His research has led to the development of multiple immunotherapies, including the first medicine approved by the U.S. Food and Drug Administration (FDA) targeting T-cell co-stimulation to treat autoimmunity and the first FDA-approved checkpoint inhibitor for the treatment of metastatic melanoma. He served as a Member of the Blue Ribbon Panel, appointed by then Vice President Joe Biden, to guide the National Cancer Moonshot Task Force Initiative and also served as a senior investigator at the National Cancer Institute of the National Institutes of Health. Dr. Bluestone was part of the team of early developers of a novel anti-CD3 monoclonal antibody, now called teplizumab, a pro-tolerogenic drug that has shown clinical activity in type 1 diabetes (“T1D”), psoriatic arthritis and the reversal of kidney transplant rejection. Dr. Bluestone previously served as the Ludwig Professor and Director of the Ben May Institute at the University of Chicago. Dr. Bluestone is a Member of the National Academy of Medicine and American Academy of Arts and Sciences, was a recipient of the prestigious Guggenheim Fellowship. Dr. Bluestone earned both his B.S. in Biology and his M.S. in Microbiology from Rutgers State University and his Ph.D. in Immunology from the Weill Cornell Graduate School of Medical Science (Sloan-Kettering Division).
Positions
- Company NameArcus Biosciences, Inc.Stock CodeRCUSPositionChairman of Scientific Advisory BoardColleagues
- TJTerry J. RosenCo-Founder, Chairman & CEO
- JCJuan Carlos JaenCo- Founder & President
- RCRobert C. GoeltzPrincipal Financial Officer & CFO
- RARichard A. MarkusChief Medical Officer
- KCK. Christopher GarciaCo-Founder & Member of Scientific Advisory Board
- KEKathryn E. FalbergIndependent Director
- YKYasunori KanekoLead Independent Director
